Taken together, these findings support the possibility that direct inhibition of the IL-6 signaling axis offers the potential to bridge such activities, one of the primary measures of success in heart failure-specific, especially arrhythmia-specific, therapy in obesity. This evidence concerns the gene IL6 and cardiac arrhythmia.